The authors review how part of the Slovenian pharmaceutical market was influenced by reference pricing. On the basis of their descriptive analysis, they argue that the reference-pricing system caused a dramatic decrease of the market shares of originators on the one hand and an increase in the share of generic drugs on the other hand.
Get full access to this article
View all access options for this article.
References
1.
AlbrehtTit, CesenMarjan, HindleDon, JakubowskiElke, KrambergerBoris, PetricVesna Kerstin, PremikMarjan, and TothMartin (2002), Health Care Systems in Transition: Slovenia.Copenhagen: European Observatory on Health Care Systems.
2.
AronssonThomas, MatsA. Bergman, and RudholmNiklas (2001), “The Impact of Generic Drug Competition on Brand Name Market Shares: Evidence from Micro Data,”Review of Industrial Organization, 19 (4), 425–35.
3.
BrekkeKurt R., AstridL. Grasdal, and HolmasTor Helge (2006), “Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?” working paper, Department of Economics, Health Economics Bergen, University of Bergen, (accessed November 28, 2006), [available at http://www.nhh.no/sam/res-publ/2006/30.pdf].
4.
DanzonPatricia (2001), “Reference Pricing: Theory and Evidence,” working paper, The Wharton School, University of Pennsylvania.
DanzonPatricia, and JonathanD. Ketcham (2003), “Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand,” National Bureau of Economic Research Working Paper No. 10007.
7.
DicksonMichael, and RedwoodHeinz (1998), “Pharmaceutical Reference Prices: How Do They Work in Practice?”Pharmaeconomics, 14 (5), 471–79.
8.
EssM. Silvia, SchneeweissSebastian, and ThomasD. Szucs (2003), “European Healthcare Policies for Controlling Drug Expenditure,”Pharmaeconomics, 21 (2), 90–103.
9.
The European Federation of Pharmaceutical Industries and Associations (2005), The Pharmaceutical Industry in Figures 2005, (accessed August 18, 2006), [available at http://www.efpia.org/6_publ/default.htm].
10.
FestićMejra (2004), “Cost Containment for Public Pharmaceutical Expenditures in the European Union,”Naše Gospodarstvo [Our Economy], 50 (1-2), 84–92.
11.
FrankRichard G., and DavidS. Salkever (1997), “Generic Entry and the Pricing of Pharmaceuticals,”Journal of Economics and Management Strategy, 6 (1), 75–90.
12.
FürstJurij (2001), “Predpisovanje zdravil v letu 2000” [“Prescribing of Drugs in 2000”], Zdravnški Vestnik [Slovene Medical Journal], 70 (10), 525–30.
13.
FürstJurij (2003), “Predpisovanje zdravil v letu 2002” [“Prescribing of Drugs in 2002”], Zdravnški Vestnik [Slovene Medical Journal], 72 (3), 117–25.
14.
FürstJurij (2004a), “Predpisovanje zdravil v letu 2003” [“Prescribing of Drugs in 2003”], Zdravnški Vestnik [Slovene Medical Journal], 73 (6), 477–85.
15.
FürstJurij (2004b), Slovenia, Pricing and Reimbursement of Pharmaceuticals.Ljubljana: HIIS Internet Resources, (accessed November 30, 2004), [available from http://www.zzzs.si].
16.
FürstJurij (2005), “Predpisovanje zdravil v letu 2004” [“Prescribing of Drugs in 2004”], Zdravnški Vestnik [Slovene Medical Journal], 74 (6), 345–50.
17.
FürstJurij, and SamalukVita (2006), “Predpisovanje zdravil v letu 2005” [“Prescribing of Drugs in 2005”], Zdravnški Vestnik [Slovene Medical Journal], 75 (6), 253–57.
18.
GiulianiGiovanni, SelkeGisbert, and GarattiniLivio (1998), “The German Experience in Reference Pricing,”Health Policy, 44 (1), 73–85.
19.
HIIS (2003), Uvedba sistema medsebojno zamenljivih zdravil z najvišjo priznano vrednostjo [The Implementation of the Interchangeable Drugs System with the Maximum Reimbursed Price]. Ljubljana: HIIS Internet Resources, (accessed August 18, 2006), [available at http://www.zzzs.si].
HuttinChristine (2002), “Experiences with Reference Pricing,”International Journal of Risk & Safety in Medicine, 15 (1-2), 85–91.
22.
Ioannides-DemosLisa L., JospehE. Ibrahim, and JohnJ. McNeil (2002), “Reference-Based Pricing Schemes, Effect on Pharmaceutical Expenditure, Resource Utilisation and Health Outcomes,”Pharmacoeconomics, 20 (9), 577–91.
23.
KalyanaramGurumurthy, and RussellS. Winer (1995), “Empirical Generalizations from Reference Price Research,”Marketing Science, 14 (3), 161–69.
24.
KanavosPanos, and ReinhardtUwe (2003), “Reference Pricing for Drugs: Is It Compatible with U.S. Health Care?”Health Affairs, 22 (3), 16–30.
25.
KingDerek R., and KanavosPanos (2002), “Encouraging the Use of Generic Medicines: Implications for Transition Economies,”Croatian Medical Journal, 43 (3), 462–69.
26.
Kogovšek VidmarTatjana (2005), “Evropski sistemi zdravstvenega varstva in zavarovanja, trg zdravil v Sloveniji in financiranje stroškov za zdravila, predpisana na Rp, lekarniška mreža ter položaj izvajalcev zdravstvenih storitev” [“European Systems of Health Insurance, Pharmaceutical Market in Slovenia and Financing of Prescription Medicines: Pharmaceutical Network and the Position of Slovenian Public Health Care Institutions”], working paper, Faculty of Pharmacy, University of Ljubljana.
27.
Lopez-CasasnovasGuilliem, and Puig-JunoyJaume (2000), “Review of Literature on Reference Pricing,”Health Policy, 54 (2), 87–123.
28.
MaioVittorio, and ManzoliLamberto (2002), “The Italian Health Care System: W.H.O. Ranking Versus Public Perception,”P&T, 27 (6), 301–308.
29.
Official Gazette of the Republic of Slovenia (2003), “Decree Adopting Criteria for Classification of Drugs,”13 (78), 11, 47–48.
30.
ParaponarisAlain, VergerPierre, and DesquinsB. (2004), “Delivering Generics Without Regulatory Incentives? Empirical Evidence from French General Practitioners About Willingness to Prescribe International Non-Propriety Names,”Health Policy, 70 (1), 23–32.
31.
PrimožičStanislav (2004), Generična in originalna zdravila v luč i regulatornih vprašanj in farmakoekonomike [Generic and Original Drugs in Light of Regulation and Pharmacoeconomics], (accessed November 30, 2005), [available from http://www2.gov.si/mz/mz-splet.nsf].
32.
PrimožičStanislav (2006), Cene zdravil v Sloveniji so v sorazmerju z evropskimi [Drug Prices in Slovenia Are in Proportion to EU Prices]. Ljubljana: Ministry of Health Internet Resources, (accessed August 18, 2006), [available at http://www.mz.gov.si].
33.
ThomasMary C., MannJim, and WilliamsSheila (1998), “The Impact of Reference Pricing on Clinical Liped Control,”New Zealand Journal of Medicine, 14 (August), 292–94.
34.
U.S. Department of Commerce, International Trade Administration (2004), Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation, (accessed October 14, 2006), [available at http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf].
35.
World Health Organization (2006), About the ATC/DDD System, (accessed August 18, 2006), [available at http://www.whocc.no/atcddd/].
